Testing immune therapy to shrink atypical moles in melanoma patients

This trial is testing whether anti-PD1 therapy — a medication that strengthens your immune system's ability to fight cancer — can help prevent melanoma from coming back or new melanomas from developing. Researchers will track how this medication affects atypical moles (irregular spots on your skin that can sometimes become melanoma) in people who have recently been diagnosed with melanoma. The hope is that by boosting your immune system, the medication may shrink these moles and prevent them from turning into cancer.

Atypical moles are warning signs that your skin is at high risk for developing melanoma. While this medication has already proven effective at preventing melanoma recurrence, researchers want to understand whether it can also help control these pre-cancerous moles and stop them from ever becoming cancer in the first place.